Food and Nanodispersible CBD: Higher Exposure Can Arrive Later
Food increased systemic CBD exposure while delaying the peak in a small study of a nanodispersible oral solution. A later peak therefore did not mean less absorption. Peak timing and total exposure describe different features of the same concentration curve.
The tested exposure
Eighteen healthy men entered a single-dose, open-label study comparing fasting and fed conditions. The administered dose was 300 mg CBD from a 150 mg/mL solution. Plasma CBD and its major oxidative metabolites were measured, and noncompartmental methods summarized the profiles.
This was a comparison of conditions for one formulation. It was not a test proving that every product marketed as ‘nano CBD’ behaves similarly.
Three pharmacokinetic quantities
Maximum concentration describes the height of the measured curve. Time to maximum describes when that height occurs. Area under the curve summarizes exposure across time. These quantities can move in different directions without contradiction.
The study reported increased CBD peak concentration and area under the curve with food, alongside delayed time to peak. The published concentration plot used eight fasted and nine fed participants, a reminder to distinguish enrollment from the observations available for a particular analysis.
What the study cannot establish
A single dose in a small, all-male healthy sample cannot determine long-term therapeutic effectiveness, rare adverse effects or the response of patients taking other medication. The absence of major adverse events during the experiment does not remove those limitations.
For exposure interpretation, obtain the actual formulation, meal condition and collection timeline. Applying a fasted curve to a fed exposure may misstate both the expected peak time and the amount reaching circulation. None of these plasma endpoints supplies a validated driving-impairment threshold.
Related analysis
See our analysis of formulation-dependent plasma exposure.
Primary research
Prasad Rao Gundugurti and colleagues. A Randomized, Single-Dose, Single-Sequence, Two-Arm (Fasting and Fed), Open-Label Study on the Oral Pharmacokinetics of a Nanodispersible Cannabidiol Solution (150 mg/mL). Medical Cannabis and Cannabinoids, 2025. DOI: 10.1159/000550104.



